107 related articles for article (PubMed ID: 36971438)
1. Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells.
Sconocchia T; Foßelteder J; Köhnke T; Majeti R; Reinisch A
J Vis Exp; 2023 Mar; (193):. PubMed ID: 36971438
[TBL] [Abstract][Full Text] [Related]
2. The TRACE-Seq method tracks recombination alleles and identifies clonal reconstitution dynamics of gene targeted human hematopoietic stem cells.
Sharma R; Dever DP; Lee CM; Azizi A; Pan Y; Camarena J; Köhnke T; Bao G; Porteus MH; Majeti R
Nat Commun; 2021 Jan; 12(1):472. PubMed ID: 33473139
[TBL] [Abstract][Full Text] [Related]
3. Highly Efficient Genome Editing of Murine and Human Hematopoietic Progenitor Cells by CRISPR/Cas9.
Gundry MC; Brunetti L; Lin A; Mayle AE; Kitano A; Wagner D; Hsu JI; Hoegenauer KA; Rooney CM; Goodell MA; Nakada D
Cell Rep; 2016 Oct; 17(5):1453-1461. PubMed ID: 27783956
[TBL] [Abstract][Full Text] [Related]
4. CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications.
Venkatesan V; Christopher AC; Karuppusamy KV; Babu P; Alagiri MKK; Thangavel S
J Vis Exp; 2022 Aug; (186):. PubMed ID: 36036597
[TBL] [Abstract][Full Text] [Related]
5. Multiplexed genetic engineering of human hematopoietic stem and progenitor cells using CRISPR/Cas9 and AAV6.
Bak RO; Dever DP; Reinisch A; Cruz Hernandez D; Majeti R; Porteus MH
Elife; 2017 Sep; 6():. PubMed ID: 28956530
[TBL] [Abstract][Full Text] [Related]
6. Genome Engineering of Hematopoietic Stem Cells Using CRISPR/Cas9 System.
Devaraju N; Rajendiran V; Ravi NS; Mohankumar KM
Methods Mol Biol; 2022; 2429():307-331. PubMed ID: 35507170
[TBL] [Abstract][Full Text] [Related]
7. Transient inhibition of 53BP1 increases the frequency of targeted integration in human hematopoietic stem and progenitor cells.
Baik R; Cromer MK; Glenn SE; Vakulskas CA; Chmielewski KO; Dudek AM; Feist WN; Klermund J; Shipp S; Cathomen T; Dever DP; Porteus MH
Nat Commun; 2024 Jan; 15(1):111. PubMed ID: 38169468
[TBL] [Abstract][Full Text] [Related]
8. Reactivation of γ-globin in adult β-YAC mice after ex vivo and in vivo hematopoietic stem cell genome editing.
Li C; Psatha N; Sova P; Gil S; Wang H; Kim J; Kulkarni C; Valensisi C; Hawkins RD; Stamatoyannopoulos G; Lieber A
Blood; 2018 Jun; 131(26):2915-2928. PubMed ID: 29789357
[TBL] [Abstract][Full Text] [Related]
9. Understanding and overcoming adverse consequences of genome editing on hematopoietic stem and progenitor cells.
Lee BC; Lozano RJ; Dunbar CE
Mol Ther; 2021 Nov; 29(11):3205-3218. PubMed ID: 34509667
[TBL] [Abstract][Full Text] [Related]
10. Editing the Sickle Cell Disease Mutation in Human Hematopoietic Stem Cells: Comparison of Endonucleases and Homologous Donor Templates.
Romero Z; Lomova A; Said S; Miggelbrink A; Kuo CY; Campo-Fernandez B; Hoban MD; Masiuk KE; Clark DN; Long J; Sanchez JM; Velez M; Miyahira E; Zhang R; Brown D; Wang X; Kurmangaliyev YZ; Hollis RP; Kohn DB
Mol Ther; 2019 Aug; 27(8):1389-1406. PubMed ID: 31178391
[TBL] [Abstract][Full Text] [Related]
11. Efficient CRISPR/Cas9-Mediated Gene Knockin in Mouse Hematopoietic Stem and Progenitor Cells.
Tran NT; Sommermann T; Graf R; Trombke J; Pempe J; Petsch K; Kühn R; Rajewsky K; Chu VT
Cell Rep; 2019 Sep; 28(13):3510-3522.e5. PubMed ID: 31553918
[TBL] [Abstract][Full Text] [Related]
12. NHEJ-Mediated Repair of CRISPR-Cas9-Induced DNA Breaks Efficiently Corrects Mutations in HSPCs from Patients with Fanconi Anemia.
Román-Rodríguez FJ; Ugalde L; Álvarez L; Díez B; Ramírez MJ; Risueño C; Cortón M; Bogliolo M; Bernal S; March F; Ayuso C; Hanenberg H; Sevilla J; Rodríguez-Perales S; Torres-Ruiz R; Surrallés J; Bueren JA; Río P
Cell Stem Cell; 2019 Nov; 25(5):607-621.e7. PubMed ID: 31543367
[TBL] [Abstract][Full Text] [Related]
13. Combined lentiviral- and RNA-mediated CRISPR/Cas9 delivery for efficient and traceable gene editing in human hematopoietic stem and progenitor cells.
Yudovich D; Bäckström A; Schmiderer L; Žemaitis K; Subramaniam A; Larsson J
Sci Rep; 2020 Dec; 10(1):22393. PubMed ID: 33372184
[TBL] [Abstract][Full Text] [Related]
14. CRISPR/Cas9-Based Disease Modeling and Functional Correction of Interleukin 7 Receptor Alpha Severe Combined Immunodeficiency in T-Lymphocytes and Hematopoietic Stem Cells.
Rai R; Steinberg Z; Romito M; Zinghirino F; Hu YT; White N; Naseem A; Thrasher AJ; Turchiano G; Cavazza A
Hum Gene Ther; 2024 Apr; 35(7-8):269-283. PubMed ID: 38251667
[TBL] [Abstract][Full Text] [Related]
15. Multiplex CRISPR/Cas9-Based Genome Editing in Human Hematopoietic Stem Cells Models Clonal Hematopoiesis and Myeloid Neoplasia.
Tothova Z; Krill-Burger JM; Popova KD; Landers CC; Sievers QL; Yudovich D; Belizaire R; Aster JC; Morgan EA; Tsherniak A; Ebert BL
Cell Stem Cell; 2017 Oct; 21(4):547-555.e8. PubMed ID: 28985529
[TBL] [Abstract][Full Text] [Related]
16. Genome-Wide Analysis of Off-Target CRISPR/Cas9 Activity in Single-Cell-Derived Human Hematopoietic Stem and Progenitor Cell Clones.
Smith RH; Chen YC; Seifuddin F; Hupalo D; Alba C; Reger R; Tian X; Araki D; Dalgard CL; Childs RW; Pirooznia M; Larochelle A
Genes (Basel); 2020 Dec; 11(12):. PubMed ID: 33322084
[TBL] [Abstract][Full Text] [Related]
17. Preclinical modeling highlights the therapeutic potential of hematopoietic stem cell gene editing for correction of SCID-X1.
Schiroli G; Ferrari S; Conway A; Jacob A; Capo V; Albano L; Plati T; Castiello MC; Sanvito F; Gennery AR; Bovolenta C; Palchaudhuri R; Scadden DT; Holmes MC; Villa A; Sitia G; Lombardo A; Genovese P; Naldini L
Sci Transl Med; 2017 Oct; 9(411):. PubMed ID: 29021165
[TBL] [Abstract][Full Text] [Related]
18. A Mutation-Agnostic Hematopoietic Stem Cell Gene Therapy for Metachromatic Leukodystrophy.
Antony JS; Daniel-Moreno A; Lamsfus-Calle A; Raju J; Kaftancioglu M; Ureña-Bailén G; Rottenberger J; Hou Y; Santhanakumaran V; Lee JH; Heumos L; Böhringer J; Krägeloh-Mann I; Handgretinger R; Mezger M
CRISPR J; 2022 Feb; 5(1):66-79. PubMed ID: 34882002
[TBL] [Abstract][Full Text] [Related]
19. Genome editing using CRISPR-Cas9 to create the HPFH genotype in HSPCs: An approach for treating sickle cell disease and β-thalassemia.
Ye L; Wang J; Tan Y; Beyer AI; Xie F; Muench MO; Kan YW
Proc Natl Acad Sci U S A; 2016 Sep; 113(38):10661-5. PubMed ID: 27601644
[TBL] [Abstract][Full Text] [Related]
20. A CRISPR/Cas9 method to generate heterozygous alleles in Saccharomyces cerevisiae.
EauClaire SF; Webb CJ
Yeast; 2019 Oct; 36(10):607-615. PubMed ID: 31301239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
